Skip to main content
SpringerLink
Log in

A Practical Guide to the Diagnosis and Management of Amenorrhoea

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

For women of reproductive age, pregnancy and lactation are the two most common physiological causes of amenorrhoea. This article concentrates on pathological causes of amenorrhoea. Primary amenorrhoea refers to the absence of menarche at the age of 16 and secondary amenorrhoea is the cessation of menses for at least 6 months in already cycling women.

Amenorrhoea is not a diagnosis but a symptom indicating anatomical, genetic and neuroendocrine abnormalities. It can be determined by two different groups of causes: (a) anatomical defects of the genital organs; (b) endocrine dysfunctions.

Both congenital and acquired anomalies in the structure of the uterus and vagina could produce amenorrhoea; nevertheless, in the vast majority of patients, amenorrhoea is related to an ovarian malfunction. Diagnostic work-up includes history, physical examination, laboratory data and imaging.

Amenorrhoea resulting from ovarian malfunction is associated with 4 distinct endocrine conditions. Hyperprolactinaemic amenorrhoea is often associated with a pituitary adenoma. Prolactin-lowering drugs, cyclical progestogen and hormone replacement therapy (HRT) are the different choices of treatment for cycle disturbance; a contraceptive pill can be used to ensure contraception, while prolactin-lowering drugs induce fertility in patients who desire pregnancy.

Hypogonadotrophic amenorrhoea is frequently associated with stress and nutritional deficiency. If this is the case the patient should simply be counselled. A sequential use of estrogen and progestogen can be suggested to prevent estrogen deficiency or for psychological reasons. If contraception is needed, oral contraception may be the choice for both cycle and fertility control. If the patient desires pregnancy, ovulation may be induced with pulsatile gonadotrophin-releasing hormone (GnRH) in patients with hypothalamic disfunction and with gonadotrophins in patients with pituitary failure.

Hypergonadotrophic amenorrhoea is the result of an ovarian failure. There is no curative therapy for these amenorrhoeas. However, a long term hypoestrogenic condition should be treated with estrogen to cure symptoms and to prevent an increased risk of cardiovascular disease and osteoporosis.

Normogonadotrophic amenorrhoea is caused by some disturbance in the pattern of pulsatile GnRH secretion. Since these women have some ovarian activity, they are not hypoestrogenic and will bleed in response to progestogen withdrawal. Most of these patients are likely to have polycystic ovarian disease (PCO). Menstrual bleeding can be induced in these women by cyclical progestogen administration or the sequential use of estrogen plus progestogen. Oral contraception is indicated not only in patients who desire to be protected against pregnancy but also in women with acne and hirsutism. These frequently present signs of hyperandrogenism are consistently improved by the ovarian suppression induced by the contraceptive pill. The beneficial effect of the pill can be reinforced by the simultaneous use of antiandrogens. Women with normogonadotrophic amenorrhoea and desiring pregnancy have a less favourable response to all forms of ovulation induction (antiestrogen, GnRH and gonadotrophin preparations).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Küster H. Uterus bipartitus solidus rudimentarius cum vagina solida. Z Geburtshilfe Gynakol 1910; 67: 692–718

    Google Scholar 

  2. Fore SR, Hammond CB, Parker RT, et al. Urologic and genital anomalies in patients with congenital absence of the vagina. Obstet Gynecol 1975; 46: 410–6

    PubMed  CAS  Google Scholar 

  3. Wilson JD, Goldstein JL. Classification of hereditary disorders of sexual development. Birth Defects 1975; 11: 1–16

    PubMed  CAS  Google Scholar 

  4. Griffin JE, Wilson JD. The syndromes of androgen resistance. N Engl J Med 1980; 302: 198–209

    Article  PubMed  CAS  Google Scholar 

  5. Toaff R, Ballas S, Traumati C. Hypomenorrhea-amenorrhea (Asherman’s syndrome). Fertil Steril 1978; 30: 379–87

    PubMed  CAS  Google Scholar 

  6. Schenker JK, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertil Steril 1982; 37: 593–610

    PubMed  CAS  Google Scholar 

  7. Frank RT. Formation of artificial vagina without operation. Am J Obstet Gynecol 1938; 35: 1053

    Google Scholar 

  8. Manuel M, Katayama KP, Jones Jr HW. The age of occurrence of gonadal tumours in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976; 124: 293–300

    PubMed  CAS  Google Scholar 

  9. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173–9

    Article  PubMed  CAS  Google Scholar 

  10. Frisch RE. Fatness, menarche and female fertility. Perspect Biol Med 1985; 28: 611–33

    PubMed  CAS  Google Scholar 

  11. Baird DT. Amenorrhoea, anovulation and dysfunctional uterine bleeding. In: DeGroot LJ, editor. Endocrinology. London, New York: WB Saunders, 1995: 2059–79

    Google Scholar 

  12. Lenton EA, Sulaiman R, Sobowale O, et al. The human menstrual cycle: plasma concentrations of prolactin, LH, FSH, oestradiol and progesterone in conceiving and non-conceiving women. J Reprod Fertil 1982; 65: 131–9

    Article  PubMed  CAS  Google Scholar 

  13. Steinkampf MP. Ultrasonography in infertility management. In: Behrman SJ, Patton Jr GW, Holz G, editors. Progress in infertility. Boston: Little Brown and Co., 1994; 339–69

    Google Scholar 

  14. Antilla L, Ding YQ, Ruutianen K, et al. Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease. Fertil Steril 1991; 55: 1057–61

    Google Scholar 

  15. Keye Jr WR, Chang RJ, Wilson CB, et al. Prolactin-secreting pituitary adenomas in women: III. Frequency and diagnosis in amenorrhoea-galactorrhea. JAMA 1980; 244: 1329–33

    Article  PubMed  Google Scholar 

  16. Burrow GN, Worzman G, Rewcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981; 304: 156–8

    Article  PubMed  CAS  Google Scholar 

  17. Blackwell RE. Hyperprolactinemia: evaluation and management. Endocrinol Metab Clin North Am 1992; 21(1): 105–24

    PubMed  CAS  Google Scholar 

  18. Molitch ME. Management of prolactinomas. Annu Rev Med 1989; 40: 225–32

    Article  PubMed  CAS  Google Scholar 

  19. Laws Jr ER. Pituitary surgery. Endocrinol Metab Clin North Am 1987; 16: 647–65

    PubMed  Google Scholar 

  20. Spark RF, Baker R, Beinfang DC. et al. Bromocriptine reduces pituitary tumour size and hypersecretion: requiem for pituitary surgery? JAMA 1982; 247: 311–6

    Article  PubMed  CAS  Google Scholar 

  21. Crosignani PG, Ferrari C, Liuzzi A, et al. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline and lisuride. Fertil Steril 1982; 37: 61–6

    PubMed  CAS  Google Scholar 

  22. Vance ML, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med 1984; 100: 78–91

    PubMed  CAS  Google Scholar 

  23. Robbins RJ. Medical management of prolactinomas. In: Olefsky JM, Robbins RJ, editors. Prolactinomas. New York: Churchill Livingstone, 1986: 97–114

    Google Scholar 

  24. Murphy FY, Vesely DL, Jerdan RM, et al. Giant invasive prolactinomas. Am J Med 1987; 83: 995–1002

    Article  PubMed  CAS  Google Scholar 

  25. Vermesh M, Fossum GT, Kletzy OA. Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 1988; 72: 693–8

    PubMed  CAS  Google Scholar 

  26. van der Lely AJ, Brownell J, Lamberts SWJ. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72: 1136–41

    Article  PubMed  Google Scholar 

  27. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904–9

    Article  PubMed  CAS  Google Scholar 

  28. Tang LCH, Sung ML, Ma HK. Hyperprolactinaemic amenorrhoea in Hong Kong. Aust NZ J Obstet Gynaecol 1983; 23: 165–9

    Article  CAS  Google Scholar 

  29. Al-Suleiman SA, Najashi S, Rahman J, et al. Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust NZ J Obstet Gynaecol 1989; 29: 176–9

    Article  CAS  Google Scholar 

  30. Diamant YZ, Yarkoni S, Evron S. Combined clomiphenebromocriptine treatment in anovulatory, oligomenorrheic and hyperprolactinemic women resistant to separate clomiphene or bromocriptine regimens. Infertility 1980; 3: 11–6

    Google Scholar 

  31. Weil C. The safety of bromocriptine in hyperprolactinemic female infertility: a literature review. Curr Med Res Opin 1986; 10: 172–95

    Article  PubMed  CAS  Google Scholar 

  32. Mattei AM, Ferrari C, Ragni G, et al. Serum prolactin and ovarian function afte discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br J Obstet Gynaecol 1984; 91: 244–50

    Article  PubMed  CAS  Google Scholar 

  33. Rassmussen C, Bergh T, Wide L, et al. Long term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinemia. Clin Endocrinol 1988; 29: 271–9

    Article  Google Scholar 

  34. Physician’s Desk Reference. Parlodel® (Sandoz). 43rd ed. New York: Medical Economics, 1989: 1888–90

    Google Scholar 

  35. Kallmann F, Schonfeld WA, Barrera SW. Genetic aspects of primary eunuchoidism. Am J Ment Defic 1944; 48: 203

    Google Scholar 

  36. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 1974; 185: 949–51

    Article  PubMed  CAS  Google Scholar 

  37. Rowe PJ, Comhaire FH, Hargreave TB, et al. WHO manual for the standardized investigation of the infertile couple. Cambridge: Cambridge University Press, 1993

    Google Scholar 

  38. Filicori M, Flamigni C, Meriggiola MC, et al. Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives. Fertil Steril 1991; 56: 1–13

    PubMed  CAS  Google Scholar 

  39. Couzinet B, Lestrat N, Brailly S, et al. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. J Clin Endocrinol Metab 1988; 66: 552–6

    Article  PubMed  CAS  Google Scholar 

  40. Layman LC, Reindollar RH. The genetics of hypogonadism. Infertil Reprod Med Clin North Am 1994; 1: 53–68

    Google Scholar 

  41. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53: 804–10

    PubMed  CAS  Google Scholar 

  42. The ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod. 1995; 10: 1549–53

    Article  Google Scholar 

  43. Adams J, Franks S, Poison DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin-releasing hormone. Lancet 1985; II: 1375–9

    Article  Google Scholar 

  44. Filicori M, Flamigni C, Cognigni G, et al. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction. Fertil Steril 1994; 62: 279–85

    PubMed  CAS  Google Scholar 

  45. Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirutism: results in a multicentered Canadian study. Fertil Steril 1986; 46: 1015–20

    PubMed  CAS  Google Scholar 

  46. Chapman MG, Dowsett M, Dewhurst CJ, et al. Spironolactone in combination with an oral contraceptive: an alternative for hirsutism. Br J Obstet Gynaecol 1985; 92: 983–5

    Article  PubMed  CAS  Google Scholar 

  47. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23: 462–9

    Article  PubMed  CAS  Google Scholar 

  48. Morcos RN, Abdul-Malak ME, Shikora E. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil Steril 1994; 61: 427–31

    PubMed  CAS  Google Scholar 

  49. Hammond MG, Halme JK, Talbert LM. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 1983; 62: 196–202

    PubMed  CAS  Google Scholar 

  50. Daly DC, Walters CA, Soto-Albors CE, et al. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984; 41: 844–8

    PubMed  CAS  Google Scholar 

  51. Connaughton JF, Garcia CR, Wallach EE. Induction of ovulation with cisclomiphene and a placebo. Obstet Gynecol 1974; 43: 697–701

    PubMed  Google Scholar 

  52. Gysler M, March CM, Mishell Jr DR, et al. A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982; 37: 161–7

    PubMed  CAS  Google Scholar 

  53. Salat-Baroux J, Antoine JM. Accidental hyperstimulation during ovulation induction. Baillieres Clin Obstet Gynaecol 1990; 4: 627–38

    Article  PubMed  CAS  Google Scholar 

  54. Hamilton-Farley D, Kiddy D, Watson H, et al. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991; 6: 1095–9

    Google Scholar 

  55. Jones D. Report of the meeting on infertility, Edinburgh. Br J Obstet Gynaecol 1994; 102: 73–6

    Google Scholar 

  56. Gjonnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984; 41: 20–5

    PubMed  CAS  Google Scholar 

  57. Armar NA, Lachelin GC. Laparoscopic ovarian diathermy: an effective treatment for anti oestrogen resistant anovulatory infertility in women with PCOS. Br J Obstet Gynaecol 1993; 100: 161–4

    Article  PubMed  CAS  Google Scholar 

  58. Dabirashrafi H, Mohamad K, Behjatnia Y, et al. Adhesion formation after ovarian electrocoagulation on patients with PCO syndrome. Fertil Steril 1991; 55: 1200–1

    PubMed  CAS  Google Scholar 

  59. Donesky BW, Adashi EY. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil Steril 1995; 63: 439–63

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Obstetrics and Gynaecology, University of Milan, Clinica ‘L. Mangiagalli’, Via Commenda 12, 20122, Milan, Italy

    Pier Giorgio Crosignani & Walter Vegetti

Authors
  1. Pier Giorgio Crosignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter Vegetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crosignani, P.G., Vegetti, W. A Practical Guide to the Diagnosis and Management of Amenorrhoea. Drugs 52, 671–681 (1996). https://doi.org/10.2165/00003495-199652050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652050-00005

Keywords

Search

Navigation